Open-Label, Randomized, Fixed-Sequence, Crossover Study to Estimate the Effect of Telaprevir and Boceprevir on Maraviroc Pharmacokinetics in Healthy Subjects
Latest Information Update: 06 May 2015
Price :
$35 *
At a glance
- Drugs Maraviroc (Primary) ; Boceprevir; Telaprevir
- Indications Hepatitis C; HIV-1 infections
- Focus Pharmacokinetics
- Sponsors ViiV Healthcare
- 18 Sep 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 29 Aug 2012 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.
- 02 Aug 2012 Actual initiation date changed from 1 Jul 2012 to 1 Jun 2012 as reported by ClinicalTrials.gov.